Abstract
Idiopathic nondementing Parkinson’s disease (PD) is marked by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area. Recent brain imaging work implicates these structures in dopamine modulated networks subserving episodic memory. These findings are of relevance to PD because they suggest that dopamine depletion contributes to the disease-dependent decline in episodic memory, and therefore, this decline should, at least partially, be remediated by dopaminergic medication. Recognition memory (RM), recollection and familiarity during recognition was examined in 17 PD patients, 12 of whom were medicated with a D2 dopamine agonist (pramipexole or ropinirole) and l-dopa, with a further 5 PD control patients on l-dopa but no D2 agonist. Memory was tested “ON” and, following a period of medication withdrawal, “OFF” and compared to a group of 14 matched healthy volunteers (HV). The HVs were also tested twice in the absence of medication. The patients on the agonists PD showed significant impairments in recollection ON- and OFF-medication, whereas the l-dopa control patients exhibited a decline in OFF-recollection only. RM and familiarity were spared in both groups ON- and OFF-medication. These findings suggest that D2 dopamine agonists (combined with l-dopa) contribute to disease-dependent episodic memory impairment.
Highlights
We report an investigation of l-dopa and second generation nonergoline dopamine agonists (“D2 agonists”) on the recollection of episodic details and the assessment of familiarity during recognition in patients with nondementing idiopathic Parkinson’s disease (PD)
This study builds on previous a previous report [1] of a selective impairment in recollection in moderate PD when optimally medicated with dopaminergic medication
The recollection of episodic details and the assessment of familiarity during recognition was examined in idiopathic, nondementing, moderate PD patients
Summary
We report an investigation of l-dopa and second generation nonergoline dopamine agonists (“D2 agonists”) on the recollection of episodic details and the assessment of familiarity during recognition in patients with nondementing idiopathic Parkinson’s disease (PD). This study builds on previous a previous report [1] of a selective impairment in recollection in moderate PD when optimally medicated with dopaminergic medication. A dissociation between recollection and familiarity in medicated PD has been reported previously, consensus is lacking regarding the direction of this dissociation. There are a number of reports [2,3,4,5] of a selective deficit in recollection; whereas others [6,7] have found a more pronounced impairment in familiarity. Recent evidence of a double dissociation between recollection and familiarity in the same study [8], albeit in different patient groups, implies that methodological differences between studies may contribute to the direction of the dissociation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
